Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 8/20 | 0.61 |
| ▸ | MMEL1 | Q495T6 | 6/20 | 0.61 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 2/20 | 0.43 |
| ▸ | TPH1 | P17752 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16133215 | 0.88 | MMEL1 (0.60) | MMEMMEL1CTSATPH1 | |
| SCHEMBL12975713 | 0.88 | MME (0.58) | MMEMMEL1NR1H4ALDH1A1HPGD | |
| SCHEMBL10197632 | 0.88 | MME (0.82) | MMEMMEL1 | |
| SCHEMBL14952871 | 0.88 | MME (0.82) | MMEMMEL1 | |
| SCHEMBL12974475 | 0.87 | MME (0.53) | MMEMMEL1NR1H4ALDH1A1HPGD | |
| SCHEMBL12974614 | 0.86 | MME (0.74) | MMEMMEL1 | |
| SCHEMBL14952808 | 0.86 | MME (0.74) | MMEMMEL1 | |
| SCHEMBL14873432 | 0.83 | MMEL1 (0.56) | MMEMMEL1CTSATPH1 | |
| SCHEMBL8552535 | 0.80 | MMEL1 (0.67) | MMEMMEL1 | |
| SCHEMBL14765516 | 0.78 | MMEL1 (0.55) | MMEMMEL1CTSATPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | MME 1/4885MMEL1 299/4885NR1H4 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.